BioSpace News Archive

Oncxerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, announced new clinical and biomarker data from its bavituximab program in an electronic poster at the European Society of Medical Oncology Congress 2021.

Baudax Bio, Inc. announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 1:15 p.m. ET.

Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the appointment of two executives to the Company’s leadership team.

Second Genome presented preclinical data demonstrating that the Company’s novel microbiome-derived peptide, SG-3-00802, can reverse resistance to anti-programmed death protein-1 therapy, illustrating that the microbiome directly interacts with the immune system to impact antitumor immunity.

Rune Labs today announced a $22.8 million Series A financing.

Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for NTLA-5001, the company’s first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer.

Biogen Inc. today announced positive topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074), a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy (SFN).

Dante Labs today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale of the business and opportunity.

Provention Bio, Inc. today announced that management will participate in a fireside chat presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 22, 2021 at 9:05 am E.T

Repligen Corporation today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc.